Recombinant human activated protein C for the postexposure treatment of ebola hemorrhagic fever

Journal of Infectious Diseases

Volumn 196, Issue SUPPL. 2, 2007, Pages

  Hensley, Lisa E ^a   Stevens, Edward L ^a   Yan, S Betty ^d   Geisbert, Joan B ^a   Macias, William L ^d   Larsen, Tom ^a   Daddario DiCaprio, Kathleen M ^a,c   Cassell, Gail H ^d   Jahrling, Peter B ^b   Geisbert, Thomas W ^b,c,e  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^d ELI LILLY AND COMPANY   (United States)

^e BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DROTRECOGIN; SODIUM CHLORIDE; OLIGOPEPTIDE; PROTEIN C; PROTEIN C ACTIVATOR PEPTIDE; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CONFERENCE PAPER; CONTROLLED STUDY; DRUG EFFICACY; EBOLA VIRUS; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; MACACA; MORTALITY; NONHUMAN; PRIORITY JOURNAL; SEPSIS; SURVIVAL; TREATMENT RESPONSE; VIREMIA; VIRUS HEMORRHAGIC FEVER; ANIMAL; ARTICLE; CENTRAL VENOUS CATHETERIZATION; DISEASE MODEL; GENETICS; ISOLATION AND PURIFICATION; PRIMATE;

ANIMALS; CATHETERIZATION, CENTRAL VENOUS; DISEASE MODELS, ANIMAL; EBOLAVIRUS; HEMORRHAGIC FEVER, EBOLA; MACACA MULATTA; OLIGOPEPTIDES; PRIMATES; PROTEIN C; RECOMBINANT PROTEINS;

EID: 38449092257     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/520598     Document Type: Conference Paper

References (48)

1. Feldmann H, Geisbert TW, Jahrling PB, et al. Filoviridae. In: Fauquet C, Mayo MA, Maniloff J, Desselberger U, Ball LA, eds. Virus taxonomy: VIIIth report of the International Committee on Taxonomy of Viruses. London: Elsevier/Academic Press, 2004:645-53.
2. Geisbert TW, Jahrling PB. Exotic emerging viral diseases: progress and challenges. Nat Med 2004; 10:S110-21.
3. Sanchez A, Geisbert TW, Feldmann H. Filoviridae: Marburg and Ebola viruses. In: Knipe DM, Howley PM, Griffin DE, et al., eds. Fields virology. 5th ed. Philadelphia: Lippincott Williams & Wilkins, 2006.
4. Feldmann H, Jones SM, Schnittler HJ, Geisbert T. Therapy and prophylaxis of Ebola virus infections. Curr Opin Investig Drugs 2005; 6: 823-30.
5. Paragas J, Geisbert TW. Development of treatment strategies to combat Ebola and Marburg viruses. Expert Rev Anti Infect Ther 2006; 4:67-76.
6. Schnittler HJ, Feldmann H. Marburg and Ebola hemorrhagic fevers: does the primary course of infection depend on the accessibility of organ-specific macrophages? Clin Infect Dis 1998; 27:404-6.
7. Bray M, Mahanty S. Ebola hemorrhagic fever and septic shock. J Infect Dis 2003; 188:1613-7.
8. Geisbert TW, Hensley LE, Larsen T, et al. Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infection. Am J Pathol 2003; 163:2347-70.
9. Geisbert TW, Young HA, Jahrling PB, Davis KJ, Kagan E, Hensley LE. Mechanisms underlying coagulation abnormalities in Ebola hemorrhagic fever: overexpression of tissue factor in primate monocytes/macrophages is a key event. J Infect Dis 2003; 188:1618-29.
10. Villinger F, Rollin PE, Brar SS, et al. Markedly elevated levels of interferon (IFN)-γ, IFN-α, interleukin (IL)-2, IL-10, and tumor necrosis factor-α associated with fatal Ebola virus infection. J Infect Dis 1999; 179(Suppl 1):S188-91.
11. Hensley LE, Young HA, Jahrling PB, Geisbert TW. Proinflammatory response during Ebola virus infection of primate models: possible involvement of the tumor necrosis factor receptor superfamily. Immunol Lett 2002; 80:169-79.
12. Sanchez A, Lukwiya M, Bausch D, et al. Analysis of human peripheral blood samples from fatal and nonfatal cases of Ebola (Sudan) hemorrhagic fever: cellular responses, virus load, and nitric oxide levels. J Virol 2004; 78:10370-7.
13. Baize S, Leroy EM, Georges AJ, et al. Inflammatory responses in Ebola virus-infected patients. Clin Exp Immunol 2002; 128:163-8.
14. Annane D, Bellissant E, Cavaillon JM. Septic shock. Lancet 2005; 365:63-78.
15. Levy MM, Fink MP, Marshall JC, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003; 31:1250-6.
16. Ulloa L, Tracey KJ. The "cytokine profile": a code for sepsis. Trends Mol Med 2005; 11:56-63.
17. Macias WL, Nelson DR. Severe protein C deficiency predicts early death in severe sepsis. Crit Care Med 2004; 32:S223-8.
18. Shorr AF, Bernard GR, Dhainaut JF, et al. Protein C concentrations in severe sepsis: an early directional change in plasma levels predicts outcome. Crit Care 2006; 10:R92.
19. Esmon CT. The protein C anticoagulant pathway. Arterioscler Thromb 1992; 12:135-45.
20. Geisbert TW, Hensley LE, Jahrling PB, et al. Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys. Lancet 2003; 362:1953-8.
21. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003; 348:1546-54.
22. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29:1303-10.
23. Laterre PF, Levy H, Clermont G, et al. Hospital mortality and resource use in subgroups of the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) trial. Crit Care Med 2004; 32:2207-18.
24. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344:699-709.
25. Beigel JH, Farrar J, Han AM, et al. Avian influenza A (H5N1) infection in humans. N Engl J Med 2005; 353:1374-85.
26. Bailey JM. Parvovirus B19 presenting with severe sepsis in a previously healthy 25-year-old female. J Am Board Fam Med 2006; 19:317-9.
27. Opal SM, Garber GE, LaRosa SP, et al. Systemic host responses in severe sepsis analyzed by causative microorganism and treatment effects of drotrecogin alfa (activated). Clin Infect Dis 2003; 37:50-8.
28. Larsen T, Stevens EL, Davis KJ, et al. Pathologic findings associated with delayed death in nonhuman primates experimentally infected with Zaire Ebola virus. J Infect Dis 2007; 196(Suppl 2):S323-8 (in this supplement).
29. Heller MV, Marta RF, Sturk A, et al. Early markers of blood coagulation and fibrinolysis activation in Argentine hemorrhagic fever. Thromb Haemost 1995; 73:368-73.
30. Walley KR, Russell JA. Protein C -1641 AA is associated with decreased survival and more organ dysfunction in severe sepsis. Crit Care Med 2007; 35:12-7.
31. Texereau J, Pene F, Chiche JD, Rousseau C, Mira JP. Importance of hemostatic gene polymorphisms for susceptibility to and outcome of severe sepsis. Crit Care Med 2004; 32:S313-9.
32. Daza-Vamenta R, Glusman G, Rowen L, Guthrie B, Geraghty DE. Genetic divergence of the rhesus macaque major histocompatibility complex. Genome Res 2004; 14:1501-15.
33. Sanchez A,Wagoner KE, Rollin PE. Sequence-based human leukocyte antigen-B typing of patients infected with Ebola virus in Uganda in 2000: identification of alleles associated with fatal and nonfatal disease outcomes. J Infect Dis 2007; 196(Suppl 2):S329-36 (in this supplement).
34. Marlar RA, Kleiss AJ, Griffin JH. Human protein C: inactivation of factors V and VIII in plasma by the activated molecule. Ann N Y Acad Sci 1981; 370:303-10.
35. Sakata Y, Curriden S, Lawrence D, Griffin JH, Loskutoff DJ. Activated protein C stimulates the fibrinolytic activity of cultured endothelial cells and decreases antiactivator activity. Proc Natl Acad Sci USA 1985; 82:1121-5.
36. Riewald M, Petrovan RJ, Donner A, Mueller BM, Ruf W. Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science 2002; 296:1880-2.
37. Esmon CT. Inflammation and the activated protein C anticoagulant pathway. Semin Thromb Hemost 2006; 32(Suppl 1):49-60.
38. Finigan JH, Dudek SM, Singleton PA, et al. Activated protein C mediates novel lung endothelial barrier enhancement: role of sphingosine 1-phosphate receptor transactivation. J Biol Chem 2005; 280:17286-93.
39. Feistritzer C, Riewald M. Endothelial barrier protection by activated protein C through PAR1-dependent sphingosine 1-phosphate receptor-1 crossactivation. Blood 2005; 105:3178-84.
40. Isobe H, Okajima K, Uchiba M, et al. Activated protein C prevents endotoxin-induced hypotension in rats by inhibiting excessive production of nitric oxide. Circulation 2001; 104:1171-5.
41. Weinstein RE, Walker FJ. Species specificity of the fibrinolytic effects of activated protein C. Thromb Res 1991; 63:123-31.
42. Fernandez JA, Xu X, Liu D, Zlokovic BV, Griffin JH. Recombinant murine-activated protein C is neuroprotective in a murine ischemic stroke model. Blood Cells Mol Dis 2003; 30:271-6.
43. Macias WL, Yan SB, Williams MD, et al. New insights into the protein C pathway: potential implications for the biological activities of drotrecogin alfa (activated). Crit Care 2005; 9(Suppl 4):S38-45.
44. Weinstein RE,Walker FJ. Effect of rabbit activated protein C on thrombin generation and fibrinolysis in a species-specific in vivo model: effect of modulation of protein S activity. Semin Thromb Hemost 1993; 19:368-77.
45. World Health Organization. Ebola haemorrhagic fever in Zaire, 1976. Bull World Health Organ 1978; 56:271-93.
46. Geisbert TW, Hensley LE, Kagan E, et al. Postexposure protection of guinea pigs against a lethal Ebola virus challenge is conferred by RNA interference. J Infect Dis 2006; 193:1650-7.
47. Daddario-DiCaprio KM, Geisbert TW, Stroher U, et al. Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates: an efficacy assessment. Lancet 2006; 367:1399-404.
48. Feldmann H, Jones SM, Daddario-Dicaprio KM, et al. Effective postexposure treatment of Ebola infection. PLoS Pathog 2007; 3:e2.